Go,
IMO Cardiogenics' inability to meet 10Q and 10K filings due dates is significant as it is a reminder of Cardiogenics' failure to properly manage its financial responsibilities.
While I believe the share price will rise if Cardiogenics issues a Press Release announcing that the first patient has been enrolled in the Beta Site clinical study; "...the whole different ballgame" for Cardiogenics does not begin until the announcement by Cardiogenics that the 200 patient Beta Site study either did or did not produce statistically significant data showing the POC Analyzer produces comparable or superior results.
If the data is positive, IMO this announcement will validate the promise of Cardiogenics' technologies -
- paramagnetic beads;
- proprietary troponin 1 cartridge
- POC Analyzer
If the data is negative or equivocal, IMO such an announcement will be the death knell for Cardiogenics.
All of us shareholders will be waiting with bated breath for this announcement.
Ante
